Provectus Pharmaceuticals Inc has received allowance of its patent application in the European Union for its lead dermatology agent, PH-10, along with a number of related agents and their use. Provectus has also received allowance for another patent application in Canada, covering applicator devices used with PH-10 and related agents. PH-10 is currently undergoing phase 2 clinical testing in New York City for the treatment of moderate to severe psoriasis, and Provectus expects to commence phase 2 testing for another indication within the next few months.